Edited by Karina Pino-Lagos, Gloria Soldevila and Maria-Luisa Alegre — Frontiers in Immunology, 2026

This Research Topic provides a broad overview of the rapidly evolving field of regulatory T cells (Tregs), exploring both their fundamental biology and their growing therapeutic potential. Tregs are essential for maintaining immune tolerance and controlling excessive immune responses, and advances in their characterization and manipulation are opening new possibilities for treating autoimmune diseases, transplantation-related disorders, cancer and other immune-mediated conditions.

The collection brings together research spanning Treg biology, metabolic reprogramming, tissue repair and regeneration, tumor immunity, leukemia, hypoxic environments, wound healing, autoimmunity and cell therapy. A major emphasis is placed on understanding the mechanisms that determine Treg suppressive activity and stability, as well as how these properties change across tissues, developmental stages and disease contexts.

Several studies focus specifically on human Tregs and their potential clinical application. The research includes detailed phenotypic characterization of Tregs from different human sources, investigation of altered Treg function in diseases such as COVID-19 and Sjögren’s syndrome, and strategies designed to create more stable and effective therapeutic Treg populations. Among these approaches are the use of Vitamin C to improve Treg stability and CRISPR-Cas9 gene editing to generate Tregs resistant to tacrolimus, potentially expanding their application in transplantation.

The collection also explores emerging mechanisms of immune regulation. Research by Moya-Guzmán et al. shows that different Treg subsets produce small extracellular vesicles (sEVs) capable of suppressing target cells in vitro. Other work introduces improved experimental models for evaluating human Treg persistence and suppressive function in vivo, helping bridge the gap between laboratory studies and future clinical therapies.

Overall, the publication reflects a field moving from understanding how Tregs regulate the immune system toward learning how to harness, expand and engineer these cells as reliable therapies. The strong focus on human Tregs, cellular stability, genetic and pharmacological manipulation, and improved experimental models illustrates the broader goal of translating decades of fundamental immunology into clinically applicable treatments.